Pathological complete response following cisplatin or carboplatin‑based neoadjuvant chemotherapy for triple‑negative breast cancer: A systematic review and meta‑analysis
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Clinical significance of androgen receptor expression in triple negative breast cancer‑an immunohistochemistry study
Prognostic value of using glucosylceramide synthase and cytochrome P450 family 1 subfamily A1 expression levels for patients with triple‑negative breast cancer following neoadjuvant chemotherapy
Cyclooxygenase‑2 expression in non‑metastatic triple‑negative breast cancer patients